Clinical trial NCT03330899: Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
Official title: A Phase I Randomized, Double-blind, Placebo-controlled, Dose Finding Clinical Trial to Evaluate the Safety and Immunogencity of H7N9 Influenza Antigen Adjuvanted With 2 Different Adjuvant Formulations in Healthy Adult Volunteers in Brazil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Influenza
H7N9 Influenza
Lead sponsor: Butantan Institute
Sponsor class: OTHER_GOV
First posted: 2017-11-06
Enrollment: 432
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .

Detailed description: Following the emergence of avian influenza A/H7N9 influenza virus in humans in China in March 2013, the WHO Essential Regulatory Laboratories prepared candidate vaccine viruses and reagents for further development and several manufacturers have developed various inactivated influenza vaccines with and without adjuvant against A/H7N9 and tested these candidates in trials in healthy adults. The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen produced by Butantan Institute in combination with 2 different adjuvants.

Eligibility criteria: Inclusion Criteria:

* Healthy male or female (non-pregnant) adults 18 through 59 years of age at the enrollment visit.
* To be available to participate in the study throughout its duration (approximately seven months).
* Healthy, as established by the medical history, physical examination, and screening laboratory evaluations.
* Capable and willing to complete Participant Diaries and willing to return for all follow-up visits.
* To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.
* For females of child-bearing potential, willing to utilize reliable birth control measures from Day 0 through at least 60 days following the last study vaccination.

Exclusion Criteria:

* Participation in another clinical trial involving any experimental therapy within the previous three months or planned enrollment in such a trial during the period of this study.
* Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control).
* Compromised immune system diseases including: HIV, Hepattis B and C, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases.
* Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements.
* Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history.
* Known systemic hypersensitivity to eggs or to any component of the vaccine.
* History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination.
* History of Guillain-Barre Syndrome or other demyelinating disease.
* Have a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines.
* Diagnosis of asthma with a history of hospitalization related to this condition in the last six months due to illness.
* Suspected or confirmed fever in the 3 days prior to vaccination or axillary temperature greater than 37.8 ° C on the day of vaccination.
* Use of corticosteroids (except topical or nasal) or other immunosuppressive drugs within 42 days before study initiation/baseline. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥10 mg of prednisone per day for over 14 days.
* Impaired coagulation due to chronic disease or due to use anticoagulant medication (warfarin or heparin) in the 7 days preceding vaccination.
* Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization from the first study vaccination until 21 days after the second vaccination.
* Have received any influenza A/H7 vaccine.
* History of asplenia.
* Have received blood products in the past 6 months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the first 21 days after vaccination.
* Any other condition that might put at risk the safety/rights of a potential participant or his/her compliance with this protocol in investigator's opinion or his representative physician.
* Laboratory values at screening equal to or greater than Grade 2 will be considered to be exclusionary. Vital signs may be performed up to three times to allow for transient conditions to resolve. Screening laboratory values that are out of range, but are considered to be due to an acute illness or process may be repeated once. Grade 1 laboratory values will be reviewed by a licensed study clinician and the clinician will determine whether the laboratory abnormality is clinically significant and should be considered exclusionary. If determined to be clinically insignificant, the study team is not required to follow the laboratory until resolution or the value is determined to be clinically stable.

Primary outcomes:
measure: Number of participants with solicited local Adverse Events over the 7-day period post each study injection.
timeFrame: 7-day period post each study injection (Days 0-6)
measure: Number of participants with solicited systemic Adverse Effects over the 7-day period post each study injection.
timeFrame: 7-day period post each study injection (Days 0-6)
measure: Number of participants with unsolicited local and/or systemic Adverse Events over the 7-day period post each study injection.
timeFrame: 7-day period post each study injection (Days 0-6)
Secondary outcomes:
measure: Number of participants with unsolicited local and/or systemic Adverse Events over the 28-day period post each study injection.
timeFrame: 28-day period post each study injection (Days 0-27)
measure: Number of participants with Serious Adverse Events over the 222-day period post second study injection.
timeFrame: 222-day period post the second study injection (Days 0-221)
measure: Number of participants that presented seroconversion at day 28, 45 and 56 post first study injection
timeFrame: 56-day period post the first study injection
measure: Number of participants that presented seroprotection at day 28, 45 and 56 post first study injection
timeFrame: 56-day period post the first study injection
measure: Geometric mean of Hemagglutination-inhibition titre at day 28, 45 and 56 post first study injection
timeFrame: 56-day period post the first study injection
Other outcomes:
Locations:
city: Ribeirao Preto
country: Brazil
facility: Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
state: SP
city: Sao Paulo
country: Brazil
facility: Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
state: SP
city: Sao Paulo
country: Brazil
facility: Centro de Pesquisa Clínica do Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - ICr/HCFMUSP
state: SP
Study officials:
affiliation: University of Sao Paulo
name: Esper Kallas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vanni T, Thome BC, Sparrow E, Friede M, Fox CB, Beckmann AM, Huynh C, Mondini G, Silveira DH, Viscondi JYK, Braga PE, Silva AD, Salomao MDG, Piorelli RO, Santos JP, Gattas VL, Lucchesi MBB, Oliveira MMM, Koike ME, Kallas EG, Campos LMA, Coelho EB, Siqueira MAM, Garcia CC, Miranda MD, Paiva TM, Timenetsky MDCST, Adami EA, Akamatsu MA, Ho PL, Precioso AR. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial. PLoS One. 2022 Oct 18;17(10):e0274943. doi: 10.1371/journal.pone.0274943. eCollection 2022.